European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 364-366 , July 2008

Churg–Strauss syndrome associated with omalizumab

  • Xavier Puéchal

      Affiliations

    • Department of Rheumatology, Le Mans General Hospital, 194 avenue Rubillard, 72000 Le Mans, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 2 43 43 26 56; fax: +33 2 43 43 28 10.
    • ,
  • Philippe Rivereau

      Affiliations

    • Department of Respiratory Diseases, Le Mans General Hospital, 194 avenue Rubillard, 72000 Le Mans, France
    • ,
  • François Vinchon

      Affiliations

    • Department of Cardiology, Le Mans General Hospital, 194 avenue Rubillard, 72000 Le Mans, France

Received 2 September 2007 ,Accepted 23 September 2007.

References 

  1. Schmitt WH, Csernok E, Kobayashi S, Klinkenborg A, Reinhold-Keller E, Gross WL. Churg–Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. 1998;41:445–452
  2. Mitsuyama H, Matsuyama W, Watanabe M, Shirahama Y, Higashimoto I, Wada T, et al. Increased expression of TRAIL receptor 3 on eosinophils in Churg–Strauss syndrome. Arthritis Rheum. 2007;56:662–673
  3. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg–Strauss syndrome. J Allergy Clin Immunol. 2007;119:1279
  4. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med. 2006;355:1281–1282
  5. Vidal E, Liozon F, Rogues AM, Cransac M, Berdha JF, Liozon E. Concurrent temporal arteritis and Churg–Strauss syndrome. J Rheumatol. 1992;19:1312–1314
  6. Amato MB, Barbas CS, Delmonte VC, Carvalho CR. Concurrent Churg–Strauss syndrome and temporal arteritis in a young patient with pulmonary nodules. Am Rev Respir Dis. 1989;139:1539–1542

PII: S0953-6205(07)00250-6

doi: 10.1016/j.ejim.2007.09.001

European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 364-366 , July 2008

Article Tools

* Image Usage & Resolution